|
Status |
Public on Feb 15, 2011 |
Title |
OCI-Ly10 control 48h |
Sample type |
RNA |
|
|
Source name |
DLBCL patient
|
Organism |
Homo sapiens |
Characteristics |
cell type: Diffuse large B-cell lymphoma cell line: OCI-Ly10 agent: DMSO control
|
Treatment protocol |
Cells were treated with panobinostat alone, decitabine alone or their combination. Following 48h of incubation with the drugs total RNA was isolated.
|
Growth protocol |
cells were grown in IMDM (Ly1 and Ly10) or RPMI (Su-DHL6) medium with 10% fetal bovine serum. Fresh medium was added every 2-3 days and the cells were kept at a cell concentration of 0.5-1 x 106/mL.
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was isolated using TRIZOL reagens
|
Label |
biotin
|
Label protocol |
standard Illumina protocol
|
|
|
Hybridization protocol |
standard Illumina protocol
|
Scan protocol |
standard Illumina protocol
|
Data processing |
Expression intensity measures went through background correction, log2 transformation, and quantile normalization methods executed by BeadStudio 3.2. software. Unsupervised clustering of gene expression data by principal component analysis was performed with the use of GenePattern software
|
|
|
Submission date |
Feb 10, 2011 |
Last update date |
Feb 15, 2011 |
Contact name |
Matko Kalac |
E-mail(s) |
[email protected]
|
Phone |
212 263 9124
|
Organization name |
NYU Medical Center
|
Department |
NYU Cancer Institute
|
Lab |
O'Connor-Smilow 1207
|
Street address |
522 1st Avenue
|
City |
New York |
State/province |
NY |
ZIP/Postal code |
10016 |
Country |
USA |
|
|
Platform ID |
GPL6947 |
Series (1) |
GSE27226 |
HDACI and DAC induce specific epigenetic profile in DLBCL |
|